levodopa inhaled Inbrija
Selected indexed studies
- Pharmacological Treatment of Tremor in Parkinson's Disease Revisited. (J Parkinsons Dis, 2023) [PMID:36847017]
- Inhaled levodopa (Inbrija) for Parkinson's disease. (Med Lett Drugs Ther, 2019) [PMID:31169799]
- Pharmaceutical Approval Update. (P T, 2019) [PMID:30828229]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacological Treatment of Tremor in Parkinson's Disease Revisited. (2023) pubmed
- Inhaled levodopa (Inbrija) for Parkinson's disease. (2019) pubmed
- Pharmaceutical Approval Update. (2019) pubmed
- Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease. (2023) pubmed
- [Inhaled levodopa: from evidence to experience]. (2024) pubmed
- Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. (2019) pubmed
- The Clinical Development of Levodopa Inhalation Powder. (2023) pubmed
- A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. (2020) pubmed
- Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease. (2020) pubmed
- Profile of inhaled levodopa and its potential in the treatment of Parkinson's disease: evidence to date. (2018) pubmed